{
    "Trade/Device Name(s)": [
        "First Sign Drug of Abuse Urine Screening Test",
        "First Sign\u2122 Drug of Abuse Urine Screening Tests"
    ],
    "Submitter Information": "WHPM, Inc.",
    "510(k) Number": "K052197",
    "Predicate Device Reference 510(k) Number(s)": [
        "K012300",
        "K043507",
        "K050593",
        "K012595",
        "K021526",
        "K022589"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJR",
        "LFG",
        "DIS",
        "LAF",
        "JXM",
        "DJG"
    ],
    "Summary Letter Date": "June 9, 2006",
    "Summary Letter Received Date": "May 12, 2006",
    "Submission Date": "May 11, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.3620"
    ],
    "Regulation Name(s)": [
        "Methadone test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Nortriptyline",
        "Secobarbital",
        "MDMA",
        "Oxazepam",
        "Methadone",
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Chromatographic immunoassay"
    ],
    "Methodologies": [
        "Qualitative immunoassay"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for First Sign Drug of Abuse Urine Screening Test for qualitative detection of six drugs of abuse in human urine using chromatographic immunoassay",
    "Indications for Use Summary": "Rapid, qualitative screening of nortriptyline, secobarbital, MDMA, oxazepam, methadone, and oxycodone in human urine for professional use; results are preliminary and require confirmatory testing",
    "fda_folder": "Toxicology"
}